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Abstract
Background: We propose a simple new method for estimating progression of a chronic disease
with multi-state properties by unifying the prevalence pool concept with the Markov process
model.
Methods: Estimation of progression rates in the multi-state model is performed using the E-M
algorithm. This approach is applied to data on Type 2 diabetes screening.
Results: Good convergence of estimations is demonstrated. In contrast to previous Markov
models, the major advantage of our proposed method is that integrating the prevalence pool
equation (that the numbers entering the prevalence pool is equal to the number leaving it) into the
likelihood function not only simplifies the likelihood function but makes estimation of parameters
stable.
Conclusion: This approach may be useful in quantifying the progression of a variety of chronic
diseases.
Background
While the relationship between exposure and outcome is
explored in traditional epidemiology, the status of the dis-
ease in question is usually expressed as a dichotomous
state: disease and non-disease. Categorizing the disease of
interest into two states, more often than not, may not only
widen the gap between epidemiologists, who are inter-
ested in the occurrence of disease, and clinicians, who are
concerned with the prognosis of disease, but also limit
investigation of the disease progression for the majority of
chronic diseases. As a matter of fact, chronic diseases usu-
ally have a multi-state property for which a dynamic pro-
gression from the early stage to the late stage proceeds
under the influence of a range of internal and external risk
factors. In order to elucidate the mechanism of disease
progression quantifying the multi-state natural history of
the disease becomes important in the new era of epidemi-
ology.
Multi-state models are increasingly used to model the pro-
gression of chronic diseases [1,2]. Such models are useful
for study of both natural history and progression of the
related disease [3,4]. Examples include the estimation of
transition rates of growth, spread of breast cancer [4], and
outcomes of cardiac transplantation [2]. Quantifying the
progression of chronic diseases from mild state to
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advanced state is also relevant to prevention and screen-
ing. The multi-state model traditionally associated with
chronic diseases has three states: no disease, preclinical
but screen-detectable disease, and symptomatic clinical
disease.
In the context of screening for chronic diseases, the esti-
mations of progression rates based on mathematical mod-
els are usually complicated and computationally
intensive. For example, Day and Walter (1984) used
screening results of breast cancer to simultaneously esti-
mate false negative cases (cases missed at screen) and the
mean sojourn time (the average duration of the screen-
detectable phase (PCDP), abbreviated as MST hereafter)
based on prevalent screen-detected cases and interval
cases (clinical cases occurring between screens) [5]. Duffy
et al. (1995) and Chen et al. (1996) also applied stochas-
tic models to estimate parameters of breast tumor progres-
sion on the basis of screen-detected and interval cancers.
Although these methods had their strengths, some major
problems still arose [1,6].
Firstly, time to pre-clinical screen-detectable phase for
prevalent screen-detected cases (identified in the first
screen) is more uncertain than that for incident screen
cases (identified in later screens) because prevalent
screen-detected cases are treated as a left-censored mode
whereas incident screen-detected cases are classified an
interval-censored mode in the context of survival analysis.
The latter usually provide more information on the occur-
rence of event than the former. To simplify the estimation
of parameters, previous methods often assume that occur-
rence of prevalence cases as in exponential distribution
which has a property of constant pre-clinical incidence.
Secondly, estimation of parameters in previous methods
needs interval cases. However, it may be difficult to obtain
interval cases in countries with incomplete registration;
one may be concerned with whether estimation of param-
eters lacking of this information could bias the result.
Although a previous study on quantifying the progression
of breast cancer demonstrates that estimation of parame-
ters using interval-censored data may yield an unbiased
result consistent with those estimates using interval cases
it is uncertain whether data on screening for other chronic
diseases has the same result. How to treat the missing
information on interval cases while relevant parameters
are estimated will be considered in this study.
Thirdly, the progression of a multi-state disease may be
affected by a set of risk factors or covariates. For example,
the onset of Type 2 diabetes may vary by sex, age, obesity
and other relevant risk factors. Previous studies on quan-
tifying the progression of chronic diseases either did not
take relevant risk factors into account [1,5,6] or consid-
ered covariates based on computationally intensive
method [7,8].
Fourthly, since certain disease states could not be directly
observed, there may be difficulty estimating the model
parameters as the models may not be identifiable. This
issue is aggravated by a lack of interval cases (cases diag-
nosed between screens). We find the application of Roth-
man prevalence pool concept and its extension plus E-M
algorithm approach can not only simplify the likelihood
function but make estimation of parameters become sta-
ble [9]. Missing information on interval cases could be
also taken into account.
In this study, a three-state Markov model and an illness-
and-death Markov model are proposed to model the pro-
gression of multi-state disease natural history. The preva-
lence pool concept proposed by Rothman is applied to
prevalent screen-detected cases to estimate parameters
dispensing with the exponential assumptions used in pre-
vious studies. To tackle the identifiable problem, an E-M
algorithm (Expectation-Maximum likelihood estimate)
approach, is proposed to take the prevalence pool equa-
tion and its extension to death as expectation equations.
Accordingly, these expectation equations in combination
with the above two Markov models are then used to esti-
mate relevant parameters. An E-M approach was first
advocated by Dempster in 1977 [10]. Since then, an E-M
algorithm had been extensively used in handling missing
data and dealing with latent variables. The major tenet of
this approach is to build up a complete likelihood func-
tion as if missing information or latent variables are
known. Then, parameters generated from expectation
equations are further applied to simplify the likelihood
function. This iterative procedure is also used to demon-
strate the convergence of parameters.
As above, the aim of this study is to demonstrate how to
estimate parameters with respect to multi-state disease
progression based on a three-state Markov model plus
Rothman prevalence pool concept or an illness-and-death
Markov model plus the extension of Rothman prevalence
pool concept under the context of an E-M algorithm
approach. A Type 2 diabetes screening regime in Taiwan is
used as an illustration. The remainder of this study is
organized as follows. We first present how to define dis-
ease natural history models for Type 2 diabetes, i.e. a
three-state Markov model and an illness-and-death
Markov model, and then delineate how to apply Rothman
prevalence pool concept and an E-M algorithm approach
to estimate parameters. Second, an illustration is given
using data from a type 2 diabetes screening regime in Tai-
wan. Third, numerical results and discussion are given
respectively.BMC Medical Informatics and Decision Making 2007, 7:34 http://www.biomedcentral.com/1472-6947/7/34
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Methods
Markov model specification
A three-state Markov model
Suppose the natural history of a chronic disease can be
defined by three states, including normal (no detectable
disease), asymptomatic (preclinical screen-detectable dis-
ease) and symptomatic (clinical disease). The progression
rates are expressed as in Figure 1, where λ1 represents the
incidence rate of asymptomatic cases and λ2 the progres-
sion rate from asymptomatic to symptomatic phase. The
inverse of λ2 is the mean sojourn time (MST).
We assume that there is no possibility of regression from
the asymptomatic phase to normal, or from the sympto-
matic phase to the asymptomatic phase. This assumption
has been extensively used in chronic disease screening
models [8,11,12].
Given transition parameters λ1 and λ2, one can develop
transition probabilities for each possible transition during
time t on the basis of the forward Kolomogorov equations
[13]. The transition probabilities for the above three-state
model are expressed in equation (1):
An illness-and-death Markov model
When death is taken into account, we further formulate a
four-state Markov model as Figure 2. The transition prob-
abilities for a four-state illness-and-death Markov can be
derived in a similar manner. The detailed algebra for tran-
sition probabilities is given in Appendix A.
Prevalence pool concept
The concept of the prevalence pool was firstly used by
Rothman and Greenland (1998) [9]. Brookmeyer (1995)
applied this concept to estimate progression rates associ-
ated with HIV and AIDS [14]. It states that, in a steady
population, the number of people entering the prevalence
pool is balanced by the number exiting from it. That is,
Inflow (to prevalence pool) = outflow (from prevalence 
pool)
Rothman used this concept to derive the relationship
between prevalence and incidence. This concept can be
extended to any equilibrium state with respect to disease
progression. In the above three-state model, for example,
a linear relationship between the asymptomatic and
symptomatic phase, in the context of screening, can be
defined as follows. The first screen in a screening regime
contains prevalent asymptomatic cases. If the total
number of subjects attending the screen is N and the prev-
alence pool (number of asymptomatic phase cases) is P,
then the size of population at risk that fed the prevalence
pool is N-P. During a very small time interval ∆t, the
number of subjects who enter the prevalence pool is λ1∆t
(N-P), where λ1 is the incidence rate of asymptomatic
phase. During the same interval ∆t, the outflow from the
prevalence pool is λ2∆t P, where λ2 is the rate of exiting
from the prevalence pool, i.e., the hazard rate of surfacing
to the symptomatic phase.
According to the above prevalence pool concept, a linear
relationship between λ1 and λ2 is obtained as follows:
Inflow = λ1∆t (N-P) = outflow = λ2∆t P
This forms what we will call hereafter the expectation
equation. The Markov model in combination with the
prevalence pool concept enables us to estimate the param-
eters using an E-M algorithm approach. In a similar way,
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A four-state illness-and-death Markov model Figure 2
A four-state illness-and-death Markov model.
            λ1                                             λ2
 Normal            asymptomatic  phase           symptomatic  phase  
( S t a t e   1 )               ( S t a t e   2 )                              ( S t a t e   3 )     
                                                             λ3
                                                      D e a t h            
                                                     ( S t a t e   4 )  
       
A three-state Markov model for a disease natural history Figure 1
A three-state Markov model for a disease natural history.
              λ1                                                  λ2
   Normal             asymptomatic  phase            symptomatic  phase  
  ( S t a t e   1 )                ( S t a t e   2 )                          ( S t a t e   3 )   BMC Medical Informatics and Decision Making 2007, 7:34 http://www.biomedcentral.com/1472-6947/7/34
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the prevalence pool concept can be applied to an illness-
and-death model which includes death as an absorbing
state.
Taking death into account, we extend the prevalence pool
concept to derive the relationship between λ2 and λ3. If P
asymptomatic phase cases are detected and the follow-up
period J is relatively short, the expected symptomatic
phase cases (CE) if the screen has not taken place is:
CE = λ2 × J × P
The above expression assumes deaths from asymptomatic
cases are rare.
Despite early intervention, some asymptomatic cases will
progress to symptomatic disease and then to death.
Assuming an average time of progression to symptomatic
disease midway through the period J, the total number of
expected death from symptomatic disease is approxi-
mately:
DE = λ3 × J/2 × CE
This gives the relationship between λ2 and λ3:
In a steady population, the relationship between λ1 and λ3
via prevalence pool equation (2) is therefore:
An E-M algorithm approach
The E-M algorithm is an iterative method for estimating
parameters in two steps: The E-step (expectation step) and
the M-step (maximization step) [10]. Let Y represent the
observed data and Z missing data or latent variables (in
our case, Z represents subjects who dropped out after the
first screen). The E-step augments the observed data Y
with the latent data Z. Doing so can simplify the likeli-
hood function in order to obtain a maximum likelihood
estimate in the M-step. Formally, we define the E-M algo-
rithm in the same way as Tanner (1996) [15]. Let λi repre-
sent the current guess to the mode of observed posterior
P(λ|Y). The observed data Y includes the first screen (Y1),
the second screen (Y2), and deaths (D). For the sake of
brevity, we let Y'1 denote a vector including Y1 and D.
Thus, P (λ|Y2, Y'1, Z) denotes the augmented and simpli-
fied posterior distribution and P (Z, Y'1|Y2, λi) denotes the
conditional predictive distribution of missing data Z and
Y'1, conditional on the current guess to the posterior
mode.
In the E-step, the computation is as follows:
In the M-step, parameters are estimated by:
In addition to missing data on interval cases, we simplify
the likelihood by indirectly estimating parameters via the
prevalence pool equation (2) and the illness-death equa-
tion (4) using data from  . Instead of estimating λ1 and
λ2 simultaneously in a three-state Markov model, we aug-
ment the observed data and simplify the likelihood func-
tion in this study by only estimating λ1 in the M-step,
given the expected λ2, which is derived from the preva-
lence pool equation. In other words, we use observed data
from the first screen in combination with the prevalence
pool equation to simplify the likelihood function based
on data from the second screen. A similar procedure is
also applied to the illness-and-death Markov model.
Since subjects may attend the first screen but may be lost
to follow up we therefore perform one analysis based on
complete data only and one estimating missing data in
the E-M algorithm.
Complete data analysis
For a three-state model, suppose we only have data on two
rounds of screening. Let N1 and N2 represent subjects
attending the first screen and the second screen, respec-
tively. The corresponding asymptomatic phase cases in
each screen are P1 and P2, respectively. Let x be the time
interval in years between the first and second screen. The
likelihood function for data from the second screen is
developed using the transition probabilities in (1). The
transition probabilities for asymptomatic phase cases and
screen negative cases are P11(t) and P12(t), respectively.
Recall that we estimate λ1 given the expected λ2, which is
estimated on the basis of the prevalence pool equation.
For a three-state model, the application of expressions (2)
and (5) to this data yield the following E-step computa-
tion:
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where
For an illness-and-death model, if the number of deaths in
P (= P1 + P2) asymptomatic phase cases is denoted as D we
used the relationship between λ1 and λ3 in expression (4)
to obtain the expected λ3 for simplifying the likelihood
function. This is in addition to using the prevalence pool
equation to determine the relationship between λ1 and λ2.
Since time of death is exactly known in principle, an
instantaneous rate, dP24(t), is required. Censored cases,
surviving to time t are modelled by 1-P24(t). The compu-
tation in the E-step is:
where P = P1 + P2
D is the number of deaths
P-D is the number of censored cases
ui: exact death time
vj: censored time
Note that λ2 and λ3 are repeatedly estimated by
In the M-step, λ1 is estimated iteratively by equation (6).
Missing data analysis
As stated earlier, some subjects drop out after the first
screen. We also use the E-M algorithm to estimate param-
eters taking this missing information into account. Fol-
lowing the principle of handling missing data proposed
by Longford et al. (2000) in diaries of alcohol consump-
tion, E-M algorithm and multiple imputations are used to
handle missing data on interval cases [16]. The procedure
is described as follows. If there are W dropouts after the
first screen, these subjects could have been in three possi-
ble states, normal, asymptomatic phase or symptomatic
phase, with respective numbers, W1, W2, and W3, between
the first screen and second screen. The W follows a multi-
nomial distribution with the corresponding probabilities:
P11(x), P12(x), and P13(X) for W1, W2, and W3, given a total
of subjects W. The expected values for the corresponding
three states are calculated as:
µi = W × P1i(X), i = 1, 2 and 3
Computation in the E-step is now:
As above, λ1 is estimated in the M-step by iteration accord-
ing to the score function as in the complete data analysis.
λ2 is estimated by iteration using the prevalence pool
equation. Estimation of parameters
The program for estimating parameters in M-step is writ-
ten using Mathematica software version 3.0 [17]. The
details of iteration between E-step and M-step are as fol-
lows. For the three-state Markov model, λ2 
(0) is first
guessed and an estimate of λ1 
(1) is obtained on the basis
of (6) and (7).
1. Substitution of λ 1 
(1) into the prevalence pool equation
(2)
yields a new estimate of λ 2 
(1)
2. Repeat procedures (1) and (2) until λ1 and λ2 converge
to four decimal points.
A similar procedure is applied to the illness-and-death
model.
An E-M approach taking covariates into account
The E-M algorithm approach can be extended to estimate
parameters making allowance for covariates affecting the
progression rates. For instance, suppose preclinical inci-
dence (λ1) increases with age. Two approaches are used to
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consider this problem. The first is based on a stratified
analysis by age, in which two separate E-M estimations are
performed in age groups < 50 and 50+. This yields inde-
pendent estimates of λ1 and λ2 for each age group.
Another method to take covariates into account is the use
of exponential hazard regression to model the effects of
covariates on the relevant progression rates. Let age,
dichotomized by two groups as in the above, be consid-
ered as a covariate and labeled by x = 1 for age over 50
years and x = 0 otherwise. The exponential hazard regres-
sion with respect to the preclinical incidence rates for the
two groups is written as follows:
λ12 = λ11 exp (β1x) (10)
The progression rates from the asymptomatic to sympto-
matic phase for two age groups (λ21 and λ22) are estimated
using the prevalence pool equation stratified by age. Thus
we have a single E-step estimating both λ11 and β, and two
M-steps at each iteration.
Variance estimation
As λ1 is estimated given λ2 in the three-state model, and
given λ2 and λ3 in the illness-and-death model, the vari-
ance of λ1 calculated through the inverse of the second
derivative of the likelihood function in the expression (7)
or (8) will be underestimated in that this is a conditional,
rather than an unconditional, estimate. Details of calcu-
lating the unconditional variance for λ1,  λ2 and λ3 are
given in Appendix B.
Results
The above method is applied to data on Type 2 diabetes
screening for subjects aged over 30 years in Taiwan. The
details of the study design and execution have been
described in full elsewhere [18]. In brief, three rounds of
screening were conducted between 1987 and 1995 with
an approximate 4-year inter-screening interval. All over-
night fasting and 2 h serum and plasma samples (pre-
served with EDTA and NaF) were collected and kept
frozen (-20°C) until analysis. Fasting plasma glucose con-
centrations were determined using the hexokmase-glu-
cose-6-phosphate dehydrogenase method with a glucose
(HK) reagent ldt (Gilford, Oberlin, OH).
Three-fixed cohorts, 1987, 1991 and 1995, were identified
according to when subjects attended their first screen.
Because few subjects attended the third screen in 1995 as
a first screen, we excluded them from analysis. Subjects
who did not take the oral glucose tolerance test (OGTT)
were also excluded from the analysis. For the 1987 cohort,
66 (8.9%) of the 678 patients tested had asymptomatic
Type 2 diabetes. Among 678 subjects, only 237 (35%)
subjects attended the second screening (1991) with com-
plete information on OGTT test. Of these, 10 had newly
diagnosed asymptomatic Type 2 diabetes. For the 1991
cohort, 39 (8.2%) of the 475 subjects were detected as
having asymptomatic Type 2 diabetes at the time of the
first screening. Thus, a total of 105 (39 + 66) asympto-
matic Type 2 diabetes cases were ascertained at first screen.
To ascertain deaths from Type 2 diabetes (ICD code 250),
the above 115 asymptomatic Type 2 diabetes patients
were followed until Dec 1997. Of the 115 subjects, 8 had
died of Type 2 diabetes. The average follow-up was 8.29
years. Table 1 summarizes the observed transitions and
corresponding transition probabilities used in the three-
state Markov model and the illness-and-death Markov
model.
Table 2 shows the estimated results for a three-state
Markov model. After three iterations the convergence of
λ1 and λ2 was met. We started from the guessed value of
Table 1: Descriptive results of early detection of Type 2 diabetes for two fixed cohorts in Puli, Taiwan
Number of Transition Type of Transition Transition probability
(1) First screen
Asymptomatic
Type 2 diabetes 105 (1 → 2, age at first screen(A)) P12(A)
Negative 1114 (1 → 1, age at first screen(A)) P11(A)
Total 1219
(2) Second screen
Asymptomatic
Type 2 diabetes 10 (1 → 2, 4 year) P12(X)
Negative 227 (1 → 1, 4 year) P11(X)
Total 237
Death 8 (1 → 4, time to death(t)) dP21(X)BMC Medical Informatics and Decision Making 2007, 7:34 http://www.biomedcentral.com/1472-6947/7/34
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 equal to 11.76% using the inverse of the ratio of
prevalence (8.6136%), estimated by cases at first screen,
to the incidence rate (1.0132%) estimated by cases at sec-
ond screen divided by 987 person-years. Given this rate,
 was estimated as 0.107594 according to the above
method. The prevalence pool equation was further
applied to estimate   as:
. The
annual preclinical incidence rate of λ1 was estimated as
1.08% (95% CI: 0.45%–2.58%). The annual progression
rate of λ2 was estimated as 11% (95% CI: 0.06–0.21). The
inverse of λ2  yielded approximately 8 years of mean
sojourn time (MST). The stratified analysis in combina-
tion with E-M algorithm gave 1.51% (95% CI: 0.49%–
4.70%) and 0.75% (95% CI: 0.19%–3.00%) of annual
preclinical incidence rate of (λ1), and 9% and 19% of
annual progression rate of λ2 for aged over 50 years and
aged under 50 years, respectively (Table 2). Subjects aged
over 50 years had a two-fold risk of occurrence of asymp-
tomatic Type 2 diabetes compared with those aged under
50 years. The approach based on exponential hazard
regression yielded similar results (Table 3). The rate ratio
of λ1 for aged over 50 years against aged under 50 years
was estimated as 2.01 (e0.70). The estimates of λ1 and λ2
based on exponential regression were very close to those
based on stratified analysis in Table 2.
Table 4 shows the estimated results taking the missing
data on interval cases into account. These estimates were
very similar to those not allowing for missing data in
Table 2. This suggests that missing information did not
affect the point estimates of λ1 and λ2 although the confi-
dence intervals allowing for missing data were narrower
than those obtained without taking missing information
into account.
The estimated results for the four-state illness-and-death
model are presented in Table 5. As in the three-state
Markov model,   and   were first guessed and 
was estimated as 0.0107594. Again,   was estimated on
the basis of the prevalence pool equation.
λ2
0 ()
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1 ()
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1 ()
11 4152
0 107594 1219 105 0 107594
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Table 3: The E-M iteration results for a Three-state Markov model taking age as a covariate in proportional hazard regression model
Parameter
Iteration β (≥ 50 yrs) (< 50 yrs)
(95% CI) λ11 λ21 λ12 λ22
----- --------- ---------- 0.0926 ---------- 0.1934
1 0.7008 0.0151 0.0926 0.0075 0.1933
2 0.7008 0.0151 0.0926 0.0075 0.1933
3 0.7008 0.0151 0.0926 0.0075 0.1933
(0.0681~7.2133)
λ11 &λ12:normal → asymptomatic.
λ21 &λ22:asymptomatic → symptomatic
Table 2: The E-M iteration results for a three-state Markov 
model
Parameter
Iteration λ1(95% CI) λ2(95% CI)
Overall
----- ---------- 0.1176
1 0.0108 0.1141
2 0.0108 0.1141
3 0.0108 0.1142
(0.0045~0.0258) (0.0614~0.2122)
≥ 50 yrs
----- --------- 0.1176
1 0.0151 0.0926
2 0.0151 0.0926
3 0.0151 0.0926
(0.0049~0.0470) (0.0416~0.2062)
<50 yrs
----- ---------- 0.1176
1 0.0075 0.1934
2 0.0075 0.1933
3 0.0075 0.1933
0.0075 0.1933
(0.0019~0.0300) (0.0732~0.5099)
λ1:normal → asymptomatic λ2:asymptomatic → symptomaticBMC Medical Informatics and Decision Making 2007, 7:34 http://www.biomedcentral.com/1472-6947/7/34
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 was estimated via the
illness-and-death equation. The estimates of λ1 and  λ2
were close to those obtained from Table 2. The annual rate
of death from Type 2 diabetes was estimated as 1.94%.
Results from the stratified analysis also showed that older
subjects had an approximately four-fold for risk for death
from Type 2 diabetes compared with younger subjects.
Discussion
Markov chain models are a natural approach to take when
modeling the transitions of patients between discrete
health states over time. Welton and Ades (2005) provided
a unified Bayesian approach to propagation of uncertainty
from both fully and partially observed event history data
to Markov model parameters [19]. In this study, we pro-
pose a new approach, based on the E-M algorithm, to esti-
mate the progression of a multi-state chronic disease
using the prevalence pool concept and Markov process
models. From the methodological viewpoint, one limita-
tion of our approach is that the prevalence pool concept
is only appropriate in a population where rates of disease
are assumed to be at a steady state and this assumption
may not necessarily apply to diabetes today, given the
recent rapid increase in incidence of diabetes in some
countries today. Furthermore, our population data sam-
ple was restricted only to subjects with complete OGTT
data, and thus some selection bias might have occurred.
Finally, Type 2 diabetes occurs in older populations for
whom death is a significant competing risk; both subjects
without disease and those with asymptomatic disease
may also die from other causes. We did not have enough
data information to formulate a more complete model
which includes competing mortality. Further studies are
needed to explore how competing risks could influence
the parameters of natural history.
Nevertheless, there are several strengths of this approach.
Firstly, it is not as computationally intensive as a single
stage estimation using the traditional Markov model. The
parameter estimation is simplified by integrating the ill-
ness and death equation into the likelihood function. The
traditional three-state model usually estimates λ1 and λ2
simultaneously using a full likelihood function. There-
fore, the likelihood function in the traditional method is
more complicated than that in the present study. In addi-
tion, simultaneous estimation of λ1 and λ2 may encounter
a collinearity problem due to a high correlation between
two parameters. This phenomenon may be observed
when there is no data on interval cases, which are some-
times unavailable for unregistered conditions such as
Type 2 diabetes. That is, it is hard to disaggregate the over-
all rate into distinct rates for each individual state transi-
tion if we have little information on the intermediate
states. Moreover, our E-M algorithm approach can also
take account of missing data on interval cases. This has
λ3
1 28
82 92 1219 105 0 0107594
() ()
(. ) ( ) .
= ×
×− ×
Table 4: The E-M iteration results for a Three-state Markov model taking missing data on interval cases into account
Parameter
Iteration λ1(95% CI λ2(95% CI)
Overall
0 0.0103 0.1089
1 0.0104 0.1107
5 0.0107 0.1135
6 0.0107 0.1135
(0.0064~0.0180) (0.0786~0.1639)
≥ 50 yrs
0 0.0151 0.1176
1 0.0151 0.0926
11 0.0151 0.0926
12 0.0151 0.0926
(0.0078~0.0294) (0.0579~0.1482)
< 50 yrs
0 0.0075 0.1176
1 0.0075 0.1934
15 0.0075 0.1933
16 0.0075 0.1933
(0.0029~0.0192) (0.0993~0.3761)
λ1:normal → asymptomatic. λ2:asymptomatic → symptomaticBMC Medical Informatics and Decision Making 2007, 7:34 http://www.biomedcentral.com/1472-6947/7/34
Page 9 of 12
(page number not for citation purposes)
not been considered in previous studies when interval
cases were not available.
Secondly, the previous parametric method of modeling
the first screen data usually required the assumption of
constant pre-clinical incidence over all ages, which may be
unrealistic. Our approach can dispense with this assump-
tion and can estimate λ1 in the E-step using an age-specific
prevalence rate.
Thirdly, results from our approach can be readily applied
to design of studies. Suppose we wish to design a rand-
omized trial of screening in this population. We estimate
λ1, λ2 and λ3 as 0.011, 0.114 and 0.019 (Table 5). From
equation (2) we would expect the prevalence at first
screen to be λ1/(λ1 + λ2) = 88/1000. These cases could be
expected to have 5-year cumulative death rate, that is, DE
= λ3 × 5/2 × λ2 × 5 = 0.027. Clinical type 2 diabetes arising
spontaneously would be expected to have a different mor-
tality rate λ4  from those arising from progression of
asymptomatic screen-detected cases. Mortality from spon-
taneous symptomatic cases can be estimated from the case
series of Chen et al. (1999) in which there were 131/766
= 0.17 deaths in an average follow-up of 3.5 years [20].
This gives an estimate for λ4 of 0.054. We would therefore
expect deaths from spontaneous interval cases of
after a little algebra. Substituting for λ1, λ2, and λ4, the
above is equal to 0.0011. We would therefore expect, per
thousand screened and then followed up for 5 years, 88 ×
0.027 + 912 × 0.0011, i.e., 3.4 deaths per thousand.
In an unscreened control group, one would expect the
number of death to be the number from progression of
those in the prevalence pool plus the number from new
cases arising, i.e.,
= 88 × 0.0586 = 6.2 per thousand.
To have 50% power to detect the difference between the
5-year death of 6.2 and 3.4 as significant, we would need
1,718 subjects per arm.
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Table 5: The E-M iteration results for the illness-and-death Markov model
Parameter
Iteration λ1(95% CI) λ2(95% CI) λ3(95% CI)
Overall
----- --------- 0.1176 0.0100
1 0.0108 0.1142 0.0194
2 0.0108 0.1142 0.0194
3 0.0108 0.1142 0.0194
(0.0045~0.0258) (0.0614~0.2122) (0.0063~0.0600)
≥ 50 yrs
----- --------- 0.1176 0.0100
1 0.0151 0.0926 0.0258
2 0.0151 0.0926 0.0258
3 0.0151 0.0926 0.0258
(0.0049~0.0469) (0.0416~0.2062) (0.0064~0.1033)
< 50 yrs
----- -------- 0.1176 0.0100
1 0.0075 0.1934 0.0068
2 0.0075 0.1933 0.0068
3 0.0075 0.1933 0.0068
(0.0019~0.0300) (0.0725~0.5149) (0.0005~0.0906)
λ1:normal → asymptomatic ; λ2:asymptomatic → symptomatic.
λ3:symptomatic → death of Type 2 diabetesBMC Medical Informatics and Decision Making 2007, 7:34 http://www.biomedcentral.com/1472-6947/7/34
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The above assumes 100% compliance and perfect sensi-
tivity. To cope with some anticipated non-compliance
and imperfect sensitivity, we might expect to have, say,
70% of the 88 per thousand in the prevalence pool. The
remaining 30% would then arise as interval cases, and the
expected death rate in the study arm over 5 years would be
62 × 0.027 + 26 × 0.0586 + 912 × 0.0011 = 4.2 per thou-
sand. For 90% power in this case, we would require 5,177
subjects per arm.
This method can also be adapted to take into account cov-
ariates affecting the progression rates of the disease by use
of stratified analysis or proportional hazard regression
model. Although the only covariate used in this study was
age, the approach can accommodate a set of covariates if
necessary. Also, the E-M algorithm used in this study was
extended to estimate missing information on interval
cases.
To check whether parameters estimated from the pro-
posed method were valid, a goodness of fit test was per-
formed to check the adequacy of models. As Table 6
shows, there were no significant differences between the
observed and expected rates for an illness-and-death
Markov model. A similar finding was observed for the
three-state model (data not shown). This suggests a good
fit of the model for empirical data.
Conclusion
In conclusion, a simple E-M algorithm approach using the
prevalence pool concept and its extension in conjunction
with the Markov model was proposed to estimate param-
eters pertaining to progression rates of chronic disease.
This approach may be useful to quantify the multi-state
natural history of certain chronic diseases and to evaluate
disease screening strategies.
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Appendix A Transition probabilities in the four 
state model
The transition probabilities for an illness-and-death
model are:
where states 1, 2, 3 and 4 represent no disease, asympto-
matic disease, symptomatic disease and death, respec-
tively, and:
P
Pt Pt Pt Pt
Pt Pt Pt
P
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Table 6: Results for the goodness of fit for the illness-and-death Markov model
Parameter Observed Expected Residual
Overall
Negative of first screen 1114 1102 11.998
Positive of first screen 105 117 -11.998
Negative of second screen 227 227.02 -0.016
Positive of second screen 10 8.04 1.9569
Death 8 6.07 1.9254
χ2 = 2.4473 P = 0.2941
≥ 50 yrs
Negative of first screen 496 483.471 12.5289
Positive of first screen 81 93.529 -12.5289
Negative of second screen 96 96.011 -0.0109
Positive of second screen 6 4.995 1.0046
Death 7 5.447 1.5534
χ2 = 2.6481 P = 0.2661
< 50 yrs
Negative of first screen 618 617.084 0.9157
Positive of first screen 24 24.916 -0.9157
Negative of second screen 131 131.007 0.0073
Positive of second screen 4 2.775 1.2246
Death 1 0.728 0.2715
χ2 = 0.6765 P = 0.7130BMC Medical Informatics and Decision Making 2007, 7:34 http://www.biomedcentral.com/1472-6947/7/34
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Appendix B
B.1 The three-state Markov model
Two parameters, λ1 and λ2, were estimated in this model.
As stated in the text, the variance of λ1 was a conditional
rather than unconditional estimate. In this case, we
should re-calculate the unconditional variance of λ1 as fol-
lows:
Var(λ1) = Var(E(λ1 | λ2) + E(Var(λ1 | λ2) (B.1)
If the asymptotic theory held, E(Var(λ1|λ2)) can be
assumed to be equal to the observed Var (λ1|λ2), which
was obtained from the inverse of the second derivative of
the likelihood function given the estimates of λ1 and λ2 in
Table 2.
The first component via the prevalence pool equation in
(B.1) was:
where P and N are numbers of positive cases and attend-
ants.
Given P and N, an unconditional variance of λ2 is needed
to calculate Var(E(λ1|λ2)). However, it is very difficult to
obtain unconditional variance of λ2 unless one has other
external data. We used an approximation method to cal-
culate an unconditional variance of λ2 as follows. Suppose
the occurrence of asymptomatic phase cases follows a
Poisson distribution, the likelihood function based on the
second screen data in Table 1 is:
The MLE of λ'1 based on the score function was estimated
0.011. The variance of λ'1 from the inverse of the second
derivative of the above likelihood function was estimated
as 0.000011. An unconditional variance of λ'2 via the
prevalence pool equation was therefore estimated as
0.000011 × (11142/1052). We believe that such an
approximation may not be unreasonable because the esti-
mate of λ'1 using the likelihood function in (B.3) was very
close to λ1 using the joint likelihood of λ1 and λ2 in Table
2.
B.2 The illness-death Markov model
If we assume λ1  conditionally independent of λ3(i.e.,
E(λ1|λ3, λ2) = E(λ1| λ2)), the unconditional variance of λ1
and λ2 can be calculated as above.
To calculate the unconditional variance of λ3, we assumed
λ3 was conditionally independent of λ1. The uncondi-
tional variance of λ3 was:
Var(λ3) = Var(E(λ3 | λ2) + E(Var(λ3 | λ2)( B . 4 )
As above, E(Var(λ3|λ2)) can be assumed to be equal to the
observed Var(λ3|λ2), obtained from the inverse of the sec-
ond derivative of the likelihood function based on MLE
estimate of λ1 conditional on λ2 and λ3 (see Table 5). Also,
using equation (3),
A similar procedure was applied to calculate the variance
of the regression coefficient β, assuming λ21 independent
of λ22.
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